Review examines genetic influences on migraine treatment efficacy and explores new therapies.
Key Points
This review investigates the relationship between genetic factors and the efficacy of migraine treatments, focusing on personalized approaches.
Literature review on migraine pathophysiology and genetic contributions, especially familial hemiplegic migraine.
Assessment of pharmacological interventions including triptans, NSAIDs, anticonvulsants, antidepressants, calcium channel blockers, and emerging therapies.
Evaluation of genetic variations on drug efficacy, metabolism, and safety.
Genetic mutations influence migraine susceptibility and treatment response.
Triptans and NSAIDs are first-line acute treatments; anticonvulsants and antidepressants are effective for prophylaxis.
Emerging therapies such as CGRP-targeted agents and gepants offer alternatives for patients not responding to traditional treatments.